Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLS NASDAQ:DNLI NASDAQ:IOVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$25.73+3.3%$25.27$16.10▼$35.72$3.25B0.692.30 million shs3.26 million shsDNLIDenali Therapeutics$16.17+3.3%$14.52$10.57▼$33.33$2.36B1.31.55 million shs1.61 million shsIOVAIovance Biotherapeutics$2.19-3.5%$2.34$1.64▼$12.51$792.45M0.8313.20 million shs10.94 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals-1.15%+7.88%-7.40%+27.60%-9.05%DNLIDenali Therapeutics+5.03%+4.96%+0.97%+1.95%-41.45%IOVAIovance Biotherapeutics+4.13%+2.71%-4.62%+17.62%-76.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$25.73+3.3%$25.27$16.10▼$35.72$3.25B0.692.30 million shs3.26 million shsDNLIDenali Therapeutics$16.17+3.3%$14.52$10.57▼$33.33$2.36B1.31.55 million shs1.61 million shsIOVAIovance Biotherapeutics$2.19-3.5%$2.34$1.64▼$12.51$792.45M0.8313.20 million shs10.94 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals-1.15%+7.88%-7.40%+27.60%-9.05%DNLIDenali Therapeutics+5.03%+4.96%+0.97%+1.95%-41.45%IOVAIovance Biotherapeutics+4.13%+2.71%-4.62%+17.62%-76.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLSApellis Pharmaceuticals 2.45Hold$33.2929.40% UpsideDNLIDenali Therapeutics 3.00Buy$33.50107.17% UpsideIOVAIovance Biotherapeutics 2.27Hold$11.90443.38% UpsideCurrent Analyst Ratings BreakdownLatest DNLI, APLS, and IOVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025APLSApellis PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025DNLIDenali TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025IOVAIovance BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025APLSApellis PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025DNLIDenali TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IOVAIovance BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/26/2025APLSApellis PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral ➝ Sell$26.00 ➝ $18.009/8/2025DNLIDenali TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight8/19/2025IOVAIovance BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/18/2025DNLIDenali TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$33.00 ➝ $30.008/12/2025IOVAIovance BiotherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLSApellis Pharmaceuticals$781.37M4.16N/AN/A$1.84 per share13.98DNLIDenali Therapeutics$330.53M7.15N/AN/A$8.53 per share1.90IOVAIovance Biotherapeutics$164.07M4.83N/AN/A$2.33 per share0.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLSApellis Pharmaceuticals-$197.88M-$1.82N/AN/AN/A-30.24%-116.09%-26.72%11/4/2025 (Estimated)DNLIDenali Therapeutics-$422.77M-$2.80N/AN/AN/AN/A-40.79%-36.39%11/5/2025 (Estimated)IOVAIovance Biotherapeutics-$372.18M-$1.23N/AN/AN/A-161.44%-52.87%-41.31%11/6/2025 (Estimated)Latest DNLI, APLS, and IOVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025IOVAIovance Biotherapeutics-$0.28N/AN/AN/A$76.20 millionN/A11/5/2025Q3 2025DNLIDenali Therapeutics-$0.76N/AN/AN/A$1.00 millionN/A11/4/2025Q3 2025APLSApellis Pharmaceuticals$0.73N/AN/AN/A$364.58 millionN/A8/11/2025Q2 2025DNLIDenali Therapeutics-$0.74-$0.72+$0.02-$0.72$5.64 millionN/A8/7/2025Q2 2025IOVAIovance Biotherapeutics-$0.29-$0.33-$0.04-$0.33$67.14 million$59.95 million7/31/2025Q2 2025APLSApellis Pharmaceuticals-$0.44-$0.33+$0.11-$0.33$187.91 million$171.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLSApellis Pharmaceuticals2.903.773.16DNLIDenali Therapeutics0.0110.2710.27IOVAIovance BiotherapeuticsN/A3.272.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLSApellis Pharmaceuticals96.29%DNLIDenali Therapeutics92.92%IOVAIovance Biotherapeutics77.03%Insider OwnershipCompanyInsider OwnershipAPLSApellis Pharmaceuticals6.50%DNLIDenali Therapeutics12.50%IOVAIovance Biotherapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLSApellis Pharmaceuticals770126.29 million118.08 millionOptionableDNLIDenali Therapeutics430146.21 million127.94 millionOptionableIOVAIovance Biotherapeutics500361.85 million324.58 millionOptionableDNLI, APLS, and IOVA HeadlinesRecent News About These CompaniesIovance Biotherapeutics (NASDAQ:IOVA) Given Sell (E+) Rating at Weiss RatingsOctober 9 at 4:35 AM | marketbeat.comIOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmOctober 8 at 3:05 PM | globenewswire.comIovance Biotherapeutics (NASDAQ:IOVA) Trading Up 6.7% - What's Next?October 8 at 1:11 PM | marketbeat.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $11.90 Average Target Price from BrokeragesOctober 7 at 2:59 AM | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 4.5% - Should You Sell?October 6 at 6:21 PM | marketbeat.comIovance Biotherapeutics (IOVA): Examining Valuation as Share Price Momentum StallsOctober 6 at 9:12 AM | finance.yahoo.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Hold" by AnalystsOctober 4, 2025 | marketbeat.comIovance Biotherapeutics (NASDAQ:IOVA) Share Price Passes Below Two Hundred Day Moving Average - What's Next?September 26, 2025 | marketbeat.comIovance Biotherapeutics, Inc. (IOVA) Targeting $1B on Amtagvi Sales amid Cost CutsSeptember 20, 2025 | finance.yahoo.comIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)September 19, 2025 | globenewswire.comCan This Beaten-Down Stock Bounce Back?September 19, 2025 | fool.comIovance Biotherapeutics (NASDAQ:IOVA) Shares Pass Below Two Hundred Day Moving Average - Here's What HappenedSeptember 18, 2025 | marketbeat.com3 Stocks to Buy Under $10 That Could Triple From HereSeptember 15, 2025 | msn.comJacobs Levy Equity Management Inc. Takes Position in Iovance Biotherapeutics, Inc. $IOVASeptember 11, 2025 | marketbeat.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Recommendation of "Hold" by BrokeragesSeptember 10, 2025 | marketbeat.comAmerican Century Companies Inc. Decreases Stake in Iovance Biotherapeutics, Inc. $IOVASeptember 9, 2025 | marketbeat.comH.C. Wainwright Keeps Buy Rating on Iovance (IOVA) After Health Canada Authorization NewsSeptember 8, 2025 | insidermonkey.comIovance Stock Faces Triple Threat from Mixed Signals and Earnings MissSeptember 5, 2025 | aktiencheck.deAIovance Biotherapeutics to Present at Upcoming ConferencesAugust 29, 2025 | globenewswire.comIovance: Thin Margins, Dilution Threat Keep Risk SkewedAugust 27, 2025 | seekingalpha.comIovance Biotherapeutics Faces Investor Backlash Over Major Equity OfferingAugust 27, 2025 | aktiencheck.deANew MarketBeat Followers Over TimeMedia Sentiment Over TimeDNLI, APLS, and IOVA Company DescriptionsApellis Pharmaceuticals NASDAQ:APLS$25.73 +0.81 (+3.25%) Closing price 04:00 PM EasternExtended Trading$25.72 0.00 (-0.02%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Denali Therapeutics NASDAQ:DNLI$16.17 +0.52 (+3.32%) Closing price 04:00 PM EasternExtended Trading$16.32 +0.15 (+0.96%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Iovance Biotherapeutics NASDAQ:IOVA$2.19 -0.08 (-3.52%) Closing price 04:00 PM EasternExtended Trading$2.21 +0.02 (+0.91%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
